IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.012 CHF | -0.98% |
|
+5.89% | -4.82% |
| May. 02 | Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond | MT |
| Apr. 26 | Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment | MT |
ETFs positioned on Idorsia Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.67% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 152 M€ | -2.37% | - | |
| 0.00% | 26 M€ | -3.22% | - | |
| 0.00% | 1 M€ | -.--% | - | |
| 0.00% | 29 M€ | -2.46% | - |
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-05-05
- Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.012
CHF
Average target price
1.724
CHF
Spread / Average Target
-14.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.82% | 398M | |
| -1.43% | 104B | |
| +8.96% | 105B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- IDIA Stock
- Funds and ETFs Idorsia Ltd
